Hiroshi Fujishima Selected Research

Inflammation (Inflammations)

1/2021	Elevated levels of prostaglandin E2 in the tears of patients with severe allergic conjunctivitis and primary cultured conjunctival cells are suppressed by ketotifen and dexamethasone.
4/2020	The Effect of Cytokine-Stimulation and Pharmacologic Intervention on PGE2 Production in Primary Human Conjunctival and Corneal Cells.
1/2020	Effects of Docosahexaenoic Acid on Chemokine Expression in Human Conjunctival Fibroblasts.
1/2016	The usefulness of measuring tear periostin for the diagnosis and management of ocular allergic diseases.
11/2010	Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
8/2009	Evaluation of conjunctival inflammatory status by confocal scanning laser microscopy and conjunctival brush cytology in patients with atopic keratoconjunctivitis (AKC).
8/2007	Conjunctival in vivo confocal scanning laser microscopy in patients with atopic keratoconjunctivitis.
4/2006	Quantitative evaluation of the early changes in ocular surface inflammation following MMC-aided papillary resection in severe allergic patients with corneal complications.
11/2005	Prostaglandin D2 induces chemotaxis in eosinophils via its receptor CRTH2 and eosinophils may cause severe ocular inflammation in patients with allergic conjunctivitis.
11/2005	Atopic ocular surface disease: implications on tear function and ocular surface mucins.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroshi Fujishima Research Topics

Disease

32	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 01/2024 - 03/2002
12	Keratoconjunctivitis 09/2020 - 04/2006
11	Conjunctival Diseases 10/2022 - 09/2005
11	Inflammation (Inflammations) 01/2021 - 10/2005
6	Pruritus (Itching) 11/2021 - 06/2006
6	Dry Eye Syndromes (Dry Eye Syndrome) 10/2019 - 11/2003
5	Hypersensitivity (Allergy) 12/2019 - 01/2002
4	Hyperemia 11/2021 - 04/2010
4	Ulcer 01/2017 - 08/2005
3	Cataract (Cataracts) 08/2020 - 03/2004
3	Conjunctivitis 02/2020 - 03/2002
3	Atopic Dermatitis (Atopic Eczema) 01/2019 - 03/2004
3	Corneal Ulcer 08/2009 - 01/2002
2	Infections 12/2023 - 06/2011
2	Foreign Bodies (Foreign Body) 01/2022 - 04/2010
1	Immediate Hypersensitivity 10/2022
1	Scleritis (Episcleritis) 04/2021
1	Pain (Aches) 04/2021
1	Necrosis 01/2021
1	Glaucoma 11/2020
1	Rare Diseases (Rare Disease) 01/2019
1	Sleep Wake Disorders 01/2018
1	Corneal Injuries 01/2016
1	Drug-Related Side Effects and Adverse Reactions 10/2014
1	Asthma (Bronchial Asthma) 07/2014
1	Urinary Incontinence 06/2011
1	Edema (Dropsy) 04/2011
1	Herpetic Keratitis 08/2009
1	Starvation 01/2008
1	Corneal Neovascularization 04/2006
1	Keratitis 04/2006

Drug/Important Bio-Agent (IBA)

18	Ophthalmic Solutions (Eye Drops)IBA 01/2023 - 11/2004
14	Tacrolimus (Prograf)FDA LinkGeneric 01/2023 - 03/2004
9	SteroidsIBA 04/2021 - 08/2009
7	SuspensionsIBA 09/2020 - 06/2006
6	Anti-Allergic Agents (Antiallergic Agents)IBA 07/2020 - 11/2004
5	AllergensIBA 10/2022 - 06/2006
4	Fluorescein (Funduscein)FDA LinkGeneric 09/2020 - 08/2005
4	Interleukin-4 (Interleukin 4)IBA 04/2020 - 03/2002
4	Immunoglobulin E (IgE)IBA 02/2020 - 04/2006
4	Cyclosporine (Ciclosporin)FDA LinkGeneric 11/2014 - 08/2009
4	LipidsIBA 11/2010 - 11/2003
3	AntigensIBA 10/2022 - 10/2014
3	InterleukinsIBA 01/2021 - 03/2002
3	Messenger RNA (mRNA)IBA 10/2019 - 10/2005
3	Interleukin-13IBA 01/2016 - 03/2002
3	bromfenac FDA Link 01/2015 - 11/2004
3	Lubricant Eye Drops (Artificial Tears)IBA 01/2015 - 09/2006
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2009 - 04/2005
3	Coloring Agents (Dyes)IBA 11/2005 - 08/2005
2	Particulate MatterIBA 01/2024 - 07/2014
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2016
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2021
2	SiliconesIBA 01/2022 - 05/2012
2	Olopatadine Hydrochloride (Patanol)FDA Link 11/2021 - 10/2014
2	Dinoprostone (PGE2)FDA Link 01/2021 - 04/2020
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 01/2008
2	ChemokinesIBA 01/2020 - 12/2009
2	Fluorometholone (FML)FDA Link 01/2017 - 06/2009
2	Prostaglandin D2IBA 08/2013 - 11/2005
2	Eosinophil Cationic ProteinIBA 04/2012 - 04/2011
2	levocabastine (Bilina)FDA Link 09/2006 - 06/2006
2	Mitomycin (Mitomycin-C)FDA LinkGeneric 04/2006 - 05/2004
2	MucinsIBA 11/2005 - 10/2005
2	Ointments (Pastes)IBA 07/2004 - 03/2004
1	Carbon MonoxideIBA 01/2024
1	Oxidants (Oxidizing Agents)IBA 01/2024
1	Angiotensin-Converting Enzyme 2IBA 12/2023
1	Serine Proteases (Serine Protease)IBA 12/2023
1	HydrogelsIBA 01/2022
1	alcaftadine FDA Link 11/2021
1	Ketotifen (Ketotifene)FDA Link 01/2021
1	LactoferrinIBA 09/2020
1	ProstaglandinsIBA 04/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2020
1	Air Pollutants (Pollutants, Air)IBA 12/2019
1	Periodic AcidIBA 10/2019
1	Cholinergic ReceptorsIBA 01/2018
1	Betamethasone (Celestone)FDA Link 01/2017
1	SolutionsIBA 11/2016
1	PeriostinIBA 01/2016
1	epinastine FDA Link 10/2014
1	Vehicle Emissions (Emissions, Vehicle)IBA 01/2013
1	NaphtholsIBA 06/2011
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2010
1	Cromolyn Sodium (Cromoglicic Acid)FDA LinkGeneric 06/2009
1	Histamine H1 AntagonistsIBA 01/2008
1	tranilastIBA 01/2008
1	CC ChemokinesIBA 01/2008
1	Histamine Receptors (Histamine Receptor)IBA 09/2006

Therapy/Procedure

4	Therapeutics 07/2020 - 01/2008
3	Slit Lamp 03/2021 - 10/2010
3	Lasers (Laser) 08/2009 - 08/2007
2	Hydrophilic Contact Lenses (Hydrophilic Contact Lens) 01/2022 - 01/2021
2	Aftercare (After-Treatment) 11/2014 - 07/2004
2	Phacoemulsification 05/2005 - 03/2004
1	Telescopes 02/2020
1	Contact Lenses 10/2019
1	Intravenous Administration 06/2011
1	Drug Therapy (Chemotherapy) 04/2011